BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces today that Jonathan Solomon, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9 - 11, 2024 at the Lotte New York Palace Hotel.
2024年9月4日，位於馬里蘭蓋瑟斯堡（GAITHERSBURG），衝擊物xBiomX Inc.（紐交所美國股票代碼：PHGE）（"衝擊物xBiomX"或"公司"），一家正在推進採用新型天然和工程專染體療法來針對特定病原細菌的臨床階段公司，今天宣佈，首席執行官Jonathan Solomon將在H.C. Wainwright第26屆全球投資大會上進行企業概述。該大會將於2024年9月9日至11日在紐約宮殿酒店舉行。
| Presentation Date: | September 9, 2024 | |
| Time: | Available on-demand starting at 7:00 AM ET | |
| Webcast Link: |
| 演示日期： | 2024年9月9日 | |
| 時間： | 從美國東部時間早上7點開始可按需使用 | |
| 網絡鏈接： |
A replay of the presentation can be found on the Company's website under Events & Presentations and will be available for 90 days:
公司網站的「事件和演示」欄目中可以找到演示的回放，將在90天內提供：
Mr. Solomon will be available for one-on-one meetings throughout the conference. To request a meeting and to register for the conference, click here:
索羅門先生將在會議期間提供一對一會議。要請求會議並註冊會議，請點擊這裏：
About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT ("BacteriOphage Lead to Treatment") platform to customize phage compositions against these targets. For more information, please visit , the content of which does not form a part of this press release.
關於BiomX
BiomX是一家處於臨床階段的公司，領導研發天然和工程噬菌體雞尾酒和個性化噬菌體治療，旨在針對和消滅導致慢性疾病的有害細菌，這是重大醫療需求的治療方法。BiomX發現和驗證專有的細菌性靶點，並應用其BOLt（「BacteriOphage Lead to Treatment」）平台，定製針對這些靶點的噬菌體組合。欲了解更多信息，請訪問，內容不構成本新聞稿的一部分。
Contacts:
BiomX, Inc.
Assaf Oron
+97254-2228901
assafo@biomx.com
聯繫人：
BiomX, Inc.
Assaf Oron
+97254-2228901
assafo@biomx.com
INVESTORS:
CORE IR
Peter Seltzberg
peters@coreir.com
投資者：
CORE IR
Peter Seltzberg
peters@coreir.com
譯文內容由第三人軟體翻譯。
